Texas Neurology
Welcome,         Profile    Billing    Logout  
 12 Trials 
54 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Berry, James M
NCT06169176: RAPA-501 Therapy for ALS Expanded Access Protocol

Available
2/3
40
US
RAPA-501 Autologous T cells
Rapa Therapeutics LLC, Massachusetts General Hospital, National Institute of Neurological Disorders and Stroke (NINDS)
Amyotrophic Lateral Sclerosis
 
 
NCT04220190: RAPA-501 Therapy for ALS

Recruiting
2/3
41
US
RAPA-501 Autologous T cells, RAPA-501 cells
Rapa Therapeutics LLC, Massachusetts General Hospital
Amyotrophic Lateral Sclerosis
07/26
06/27
EPISOD1, NCT06100276: Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants with SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)

Recruiting
1/2
20
US
AMT-162
UniQure Biopharma B.V.
Amyotrophic Lateral Sclerosis
09/26
03/31
NCT04081714: Intermediate Expanded Access Protocol CNMAu8.EAP03

Available
N/A
US
CNM-Au8, Nanocrystalline gold
Clene Nanomedicine, University of Texas, Southwestern Medical Center at Dallas
Multiple Sclerosis
 
 
NCT05597436: Intermediate-Sized Expanded Access Study

No Longer Available
N/A
US
Trehalose, SLS-005 Intravenous Trehalose Injection 90.5 mg/mL
Seelos Therapeutics, Inc., Massachusetts General Hospital, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH)
Amyotrophic Lateral Sclerosis
 
 
CNMAu8.EAP02, NCT05281484: Two Intermediate Expanded Access Protocols (EAP) CNMAu8.EAP01 and for ALS

Available
N/A
US
CNM-Au8, Nanocrystalline gold
Clene Nanomedicine
Amyotrophic Lateral Sclerosis
 
 
REFINE-ALS, NCT04259255: Radicava® (Edaravone) Findings in Biomarkers From ALS

Active, not recruiting
N/A
300
Canada, US
Edaravone (Radicava®/Radicava ORS®), Radicava®, Radicava ORS®
Mitsubishi Tanabe Pharma America Inc., Massachusetts General Hospital
Amyotrophic Lateral Sclerosis, ALS
03/24
03/24
Swenson, Andrea
COURAGE-ALS, NCT04944784 / 2020-004040-29: A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)

Terminated
3
489
Europe, Canada, US, RoW
Reldesemtiv, Placebo
Cytokinetics
Amyotrophic Lateral Sclerosis
07/23
07/23
NCT06169176: RAPA-501 Therapy for ALS Expanded Access Protocol

Available
2/3
40
US
RAPA-501 Autologous T cells
Rapa Therapeutics LLC, Massachusetts General Hospital, National Institute of Neurological Disorders and Stroke (NINDS)
Amyotrophic Lateral Sclerosis
 
 
NCT06408727: Intermediate Expanded Access Protocol CNMAu8.EAP04

Available
N/A
US
CNM-Au8
Clene Nanomedicine, National Institute of Neurological Disorders and Stroke (NINDS)
ALS, Amyotrophic Lateral Sclerosis, PALS
 
 
NCT05597436: Intermediate-Sized Expanded Access Study

No Longer Available
N/A
US
Trehalose, SLS-005 Intravenous Trehalose Injection 90.5 mg/mL
Seelos Therapeutics, Inc., Massachusetts General Hospital, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH)
Amyotrophic Lateral Sclerosis
 
 
Morgan, Todd M
GUNS, NCT04812366: Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer

Recruiting
2
315
Canada, US
Apalutamide 60mg Tab, Abiraterone Acetate 250mg, Prednisone 5mg Tab, Docetaxel, Niraparib 100mg Oral Capsule, Atezolizumab
University of British Columbia, Janssen Inc., University Health Network, Toronto
Prostate Cancer
04/26
04/26
BRCAAway, NCT03012321: Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

Active, not recruiting
2
70
US
Olaparib, Lynparza, Abiraterone Acetate, Prednisone
Northwestern University, AstraZeneca, National Cancer Institute (NCI)
Prostate Cancer Metastatic Castration-Resistant, Abnormal DNA Repair, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer
12/26
01/27
G-MINOR, NCT02783950: Genomics in Michigan Impacting Observation or Radiation

Completed
N/A
356
US
Decipher Prostate Cancer Classifier, Decipher Post-Op
University of Michigan Rogel Cancer Center, Michigan Urological Surgery Improvement Collaborative (MUSIC), GenomeDx Biosciences Corp
Prostate Cancer
02/20
04/24
NCT04396808: Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer

Recruiting
N/A
900
US
Decipher, Decipher Prostate Cancer Classifier, Prolaris, Prolaris Prostate Cancer Test, Oncotype Dx Genomic Prostate Score (GPS), Standard of care (askMUSIC score), askMUSIC score
University of Michigan Rogel Cancer Center, National Institutes of Health (NIH), Myrexis Inc., Veracyte, Inc., MDx Health
Prostate Cancer
07/25
07/25
TARGET-HCC, NCT02954094: A Longitudinal Observational Study of the Natural History and Management of Patients With HCC

Recruiting
N/A
10000
Europe, US
Target PharmaSolutions, Inc.
Hepatocellular Cancer
10/25
10/25
NCT03692897: An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection

Recruiting
N/A
5000
Canada, US
All approved therapies for the treatment of Chronic Hepatitis B (CHB)
Target PharmaSolutions, Inc.
Hepatitis B, Hepatitis, Liver Diseases
01/26
01/26
Heitzman, Daragh
COURAGE-ALS, NCT04944784 / 2020-004040-29: A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)

Terminated
3
489
Europe, Canada, US, RoW
Reldesemtiv, Placebo
Cytokinetics
Amyotrophic Lateral Sclerosis
07/23
07/23
COURAGE OLE, NCT05442775 / 2021-004727-33: A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)

Terminated
3
71
Europe, Canada, US, RoW
Reldesemtiv
Cytokinetics, Cytokinetics Inc
Amyotrophic Lateral Sclerosis
06/23
06/23
NCT06450886: Long-term Extension Study of Ulviprubart (ABC008) in Subjects with Inclusion Body Myositis

Active, not recruiting
2/3
270
US, RoW
Ulviprubart (ABC008)
Abcuro, Inc.
Inclusion Body Myositis (IBM)
01/29
04/29
NCT05721573: A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

Active, not recruiting
2/3
231
Europe, Canada, US, RoW
ABC008
Abcuro, Inc., Syneos Health
Inclusion Body Myositis
11/25
12/25
NCT06408727: Intermediate Expanded Access Protocol CNMAu8.EAP04

Available
N/A
US
CNM-Au8
Clene Nanomedicine, National Institute of Neurological Disorders and Stroke (NINDS)
ALS, Amyotrophic Lateral Sclerosis, PALS
 
 
NCT05597436: Intermediate-Sized Expanded Access Study

No Longer Available
N/A
US
Trehalose, SLS-005 Intravenous Trehalose Injection 90.5 mg/mL
Seelos Therapeutics, Inc., Massachusetts General Hospital, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH)
Amyotrophic Lateral Sclerosis
 
 
CNMAu8.EAP02, NCT05281484: Two Intermediate Expanded Access Protocols (EAP) CNMAu8.EAP01 and for ALS

Available
N/A
US
CNM-Au8, Nanocrystalline gold
Clene Nanomedicine
Amyotrophic Lateral Sclerosis
 
 
Arcila-Londono, Ximena
COURAGE-ALS, NCT04944784 / 2020-004040-29: A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)

Terminated
3
489
Europe, Canada, US, RoW
Reldesemtiv, Placebo
Cytokinetics
Amyotrophic Lateral Sclerosis
07/23
07/23
COURAGE OLE, NCT05442775 / 2021-004727-33: A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)

Terminated
3
71
Europe, Canada, US, RoW
Reldesemtiv
Cytokinetics, Cytokinetics Inc
Amyotrophic Lateral Sclerosis
06/23
06/23
XT-150-1-0402, NCT06704347: Safety Study of XT-150 in Participants with ALS

Not yet recruiting
1
8
US
XT-150
Xalud Therapeutics, Inc.
Amyotrophic Lateral Sclerosis (ALS)
06/26
06/26
CNMAu8.EAP02, NCT05281484: Two Intermediate Expanded Access Protocols (EAP) CNMAu8.EAP01 and for ALS

Available
N/A
US
CNM-Au8, Nanocrystalline gold
Clene Nanomedicine
Amyotrophic Lateral Sclerosis
 
 
Wagoner, Mary
COMBAT-ALS, NCT04057898 / 2019-003549-14: Evaluation of MN-166 (ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients with ALS

Recruiting
2/3
230
Canada, US
MN-166, ibudilast, placebo
MediciNova
Amyotrophic Lateral Sclerosis
12/25
12/26
Duthie, Beverley
CNMAu8.EAP02, NCT05281484: Two Intermediate Expanded Access Protocols (EAP) CNMAu8.EAP01 and for ALS

Available
N/A
US
CNM-Au8, Nanocrystalline gold
Clene Nanomedicine
Amyotrophic Lateral Sclerosis
 
 
Ward, Michelle
NCT06408727: Intermediate Expanded Access Protocol CNMAu8.EAP04

Available
N/A
US
CNM-Au8
Clene Nanomedicine, National Institute of Neurological Disorders and Stroke (NINDS)
ALS, Amyotrophic Lateral Sclerosis, PALS
 
 
CNMAu8.EAP02, NCT05281484: Two Intermediate Expanded Access Protocols (EAP) CNMAu8.EAP01 and for ALS

Available
N/A
US
CNM-Au8, Nanocrystalline gold
Clene Nanomedicine
Amyotrophic Lateral Sclerosis
 
 
Carlson, Danielle
NCT06450886: Long-term Extension Study of Ulviprubart (ABC008) in Subjects with Inclusion Body Myositis

Active, not recruiting
2/3
270
US, RoW
Ulviprubart (ABC008)
Abcuro, Inc.
Inclusion Body Myositis (IBM)
01/29
04/29
NCT05721573: A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

Active, not recruiting
2/3
231
Europe, Canada, US, RoW
ABC008
Abcuro, Inc., Syneos Health
Inclusion Body Myositis
11/25
12/25
Nasri, Mohamad
NCT06408727: Intermediate Expanded Access Protocol CNMAu8.EAP04

Available
N/A
US
CNM-Au8
Clene Nanomedicine, National Institute of Neurological Disorders and Stroke (NINDS)
ALS, Amyotrophic Lateral Sclerosis, PALS
 
 
Nagaraj, Arun
REMODEL-1, NCT05147220 / 2020-005899-36: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting
3
800
Europe, US, RoW
Remibrutinib, LOU064, Teriflunomide
Novartis Pharmaceuticals, Novartis Pharma AG
Relapsing Multiple Sclerosis
04/26
10/30
NCT05671055: CogMS - A Real-world Study Into Cognitive Impairment in People With Multiple Sclerosis

Completed
N/A
300
Europe, US
Custom study version of icompanion app
icometrix, Bristol-Myers Squibb
Multiple Sclerosis
12/23
12/23
Heitzman
NCT05721573: A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

Active, not recruiting
2/3
231
Europe, Canada, US, RoW
ABC008
Abcuro, Inc., Syneos Health
Inclusion Body Myositis
11/25
12/25
Halawani, Hanan Al
NCT06450886: Long-term Extension Study of Ulviprubart (ABC008) in Subjects with Inclusion Body Myositis

Active, not recruiting
2/3
270
US, RoW
Ulviprubart (ABC008)
Abcuro, Inc.
Inclusion Body Myositis (IBM)
01/29
04/29
NCT05721573: A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

Active, not recruiting
2/3
231
Europe, Canada, US, RoW
ABC008
Abcuro, Inc., Syneos Health
Inclusion Body Myositis
11/25
12/25
Coriddi, Angela
CNMAu8.EAP02, NCT05281484: Two Intermediate Expanded Access Protocols (EAP) CNMAu8.EAP01 and for ALS

Available
N/A
US
CNM-Au8, Nanocrystalline gold
Clene Nanomedicine
Amyotrophic Lateral Sclerosis
 
 
Aburashed, Rany
REMODEL-1, NCT05147220 / 2020-005899-36: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting
3
800
Europe, US, RoW
Remibrutinib, LOU064, Teriflunomide
Novartis Pharmaceuticals, Novartis Pharma AG
Relapsing Multiple Sclerosis
04/26
10/30
NCT05686044: A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD

Completed
2/3
320
US
Buntanetap/Posiphen, Posiphen Tartrate, Placebo
Annovis Bio Inc.
Alzheimer Disease
02/24
02/24
Hua, Vivian
NCT06450886: Long-term Extension Study of Ulviprubart (ABC008) in Subjects with Inclusion Body Myositis

Active, not recruiting
2/3
270
US, RoW
Ulviprubart (ABC008)
Abcuro, Inc.
Inclusion Body Myositis (IBM)
01/29
04/29
NCT05721573: A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

Active, not recruiting
2/3
231
Europe, Canada, US, RoW
ABC008
Abcuro, Inc., Syneos Health
Inclusion Body Myositis
11/25
12/25
Naddaf, Elie
NCT05721573: A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

Active, not recruiting
2/3
231
Europe, Canada, US, RoW
ABC008
Abcuro, Inc., Syneos Health
Inclusion Body Myositis
11/25
12/25
RESET-MG, NCT06359041: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis

Recruiting
1/2
12
US
CABA-201
Cabaletta Bio
Generalized Myasthenia Gravis (gMG)
09/29
09/29
Arroyo, Victor Bolivar
REMODEL-1, NCT05147220 / 2020-005899-36: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting
3
800
Europe, US, RoW
Remibrutinib, LOU064, Teriflunomide
Novartis Pharmaceuticals, Novartis Pharma AG
Relapsing Multiple Sclerosis
04/26
10/30
Ngwueke, Agatha
REMODEL-1, NCT05147220 / 2020-005899-36: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting
3
800
Europe, US, RoW
Remibrutinib, LOU064, Teriflunomide
Novartis Pharmaceuticals, Novartis Pharma AG
Relapsing Multiple Sclerosis
04/26
10/30
ART-AIN IIB-2, NCT06206564: Artesunate Ointment for the Treatment of Anal HSIL in HIV-negative Participants

Recruiting
2
48
US
Artesunate ointment, Artesunic acid, Dihydroartemisinin (DHA), Artemisinin, Placebo, placebo ointment
Frantz Viral Therapeutics, LLC, Laser Surgery Care, LLC, Anal Dysplasia Clinic MidWest
Anal High-grade Squamous Intraepithelial Lesion, Anal HSIL, Anal HPV Infection
12/25
12/25
Rucker, Haley
MAGIC, NCT06282159: A Phase 2 Study to Evaluate DNTH103 in Adults with Generalized Myasthenia Gravis

Recruiting
2
60
Europe, Canada, US, RoW
DNTH103, Placebo
Dianthus Therapeutics
Myasthenia Gravis, Generalized
12/25
12/27
Rice, Danielle
REMODEL-1, NCT05147220 / 2020-005899-36: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting
3
800
Europe, US, RoW
Remibrutinib, LOU064, Teriflunomide
Novartis Pharmaceuticals, Novartis Pharma AG
Relapsing Multiple Sclerosis
04/26
10/30
Poulos, Cati
NCT06069934: Pridopidine in Amyotrophic Lateral Sclerosis (EAP 2)

No Longer Available
N/A
US
Pridopidine
Prilenia, Massachusetts General Hospital, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH)
Amyotrophic Lateral Sclerosis
 
 
Pinal, Amanda
NCT06069934: Pridopidine in Amyotrophic Lateral Sclerosis (EAP 2)

No Longer Available
N/A
US
Pridopidine
Prilenia, Massachusetts General Hospital, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH)
Amyotrophic Lateral Sclerosis
 
 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Berry, James M
NCT06169176: RAPA-501 Therapy for ALS Expanded Access Protocol

Available
2/3
40
US
RAPA-501 Autologous T cells
Rapa Therapeutics LLC, Massachusetts General Hospital, National Institute of Neurological Disorders and Stroke (NINDS)
Amyotrophic Lateral Sclerosis
 
 
NCT04220190: RAPA-501 Therapy for ALS

Recruiting
2/3
41
US
RAPA-501 Autologous T cells, RAPA-501 cells
Rapa Therapeutics LLC, Massachusetts General Hospital
Amyotrophic Lateral Sclerosis
07/26
06/27
EPISOD1, NCT06100276: Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants with SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)

Recruiting
1/2
20
US
AMT-162
UniQure Biopharma B.V.
Amyotrophic Lateral Sclerosis
09/26
03/31
NCT04081714: Intermediate Expanded Access Protocol CNMAu8.EAP03

Available
N/A
US
CNM-Au8, Nanocrystalline gold
Clene Nanomedicine, University of Texas, Southwestern Medical Center at Dallas
Multiple Sclerosis
 
 
NCT05597436: Intermediate-Sized Expanded Access Study

No Longer Available
N/A
US
Trehalose, SLS-005 Intravenous Trehalose Injection 90.5 mg/mL
Seelos Therapeutics, Inc., Massachusetts General Hospital, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH)
Amyotrophic Lateral Sclerosis
 
 
CNMAu8.EAP02, NCT05281484: Two Intermediate Expanded Access Protocols (EAP) CNMAu8.EAP01 and for ALS

Available
N/A
US
CNM-Au8, Nanocrystalline gold
Clene Nanomedicine
Amyotrophic Lateral Sclerosis
 
 
REFINE-ALS, NCT04259255: Radicava® (Edaravone) Findings in Biomarkers From ALS

Active, not recruiting
N/A
300
Canada, US
Edaravone (Radicava®/Radicava ORS®), Radicava®, Radicava ORS®
Mitsubishi Tanabe Pharma America Inc., Massachusetts General Hospital
Amyotrophic Lateral Sclerosis, ALS
03/24
03/24
Swenson, Andrea
COURAGE-ALS, NCT04944784 / 2020-004040-29: A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)

Terminated
3
489
Europe, Canada, US, RoW
Reldesemtiv, Placebo
Cytokinetics
Amyotrophic Lateral Sclerosis
07/23
07/23
NCT06169176: RAPA-501 Therapy for ALS Expanded Access Protocol

Available
2/3
40
US
RAPA-501 Autologous T cells
Rapa Therapeutics LLC, Massachusetts General Hospital, National Institute of Neurological Disorders and Stroke (NINDS)
Amyotrophic Lateral Sclerosis
 
 
NCT06408727: Intermediate Expanded Access Protocol CNMAu8.EAP04

Available
N/A
US
CNM-Au8
Clene Nanomedicine, National Institute of Neurological Disorders and Stroke (NINDS)
ALS, Amyotrophic Lateral Sclerosis, PALS
 
 
NCT05597436: Intermediate-Sized Expanded Access Study

No Longer Available
N/A
US
Trehalose, SLS-005 Intravenous Trehalose Injection 90.5 mg/mL
Seelos Therapeutics, Inc., Massachusetts General Hospital, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH)
Amyotrophic Lateral Sclerosis
 
 
Morgan, Todd M
GUNS, NCT04812366: Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer

Recruiting
2
315
Canada, US
Apalutamide 60mg Tab, Abiraterone Acetate 250mg, Prednisone 5mg Tab, Docetaxel, Niraparib 100mg Oral Capsule, Atezolizumab
University of British Columbia, Janssen Inc., University Health Network, Toronto
Prostate Cancer
04/26
04/26
BRCAAway, NCT03012321: Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

Active, not recruiting
2
70
US
Olaparib, Lynparza, Abiraterone Acetate, Prednisone
Northwestern University, AstraZeneca, National Cancer Institute (NCI)
Prostate Cancer Metastatic Castration-Resistant, Abnormal DNA Repair, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer
12/26
01/27
G-MINOR, NCT02783950: Genomics in Michigan Impacting Observation or Radiation

Completed
N/A
356
US
Decipher Prostate Cancer Classifier, Decipher Post-Op
University of Michigan Rogel Cancer Center, Michigan Urological Surgery Improvement Collaborative (MUSIC), GenomeDx Biosciences Corp
Prostate Cancer
02/20
04/24
NCT04396808: Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer

Recruiting
N/A
900
US
Decipher, Decipher Prostate Cancer Classifier, Prolaris, Prolaris Prostate Cancer Test, Oncotype Dx Genomic Prostate Score (GPS), Standard of care (askMUSIC score), askMUSIC score
University of Michigan Rogel Cancer Center, National Institutes of Health (NIH), Myrexis Inc., Veracyte, Inc., MDx Health
Prostate Cancer
07/25
07/25
TARGET-HCC, NCT02954094: A Longitudinal Observational Study of the Natural History and Management of Patients With HCC

Recruiting
N/A
10000
Europe, US
Target PharmaSolutions, Inc.
Hepatocellular Cancer
10/25
10/25
NCT03692897: An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection

Recruiting
N/A
5000
Canada, US
All approved therapies for the treatment of Chronic Hepatitis B (CHB)
Target PharmaSolutions, Inc.
Hepatitis B, Hepatitis, Liver Diseases
01/26
01/26
Heitzman, Daragh
COURAGE-ALS, NCT04944784 / 2020-004040-29: A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)

Terminated
3
489
Europe, Canada, US, RoW
Reldesemtiv, Placebo
Cytokinetics
Amyotrophic Lateral Sclerosis
07/23
07/23
COURAGE OLE, NCT05442775 / 2021-004727-33: A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)

Terminated
3
71
Europe, Canada, US, RoW
Reldesemtiv
Cytokinetics, Cytokinetics Inc
Amyotrophic Lateral Sclerosis
06/23
06/23
NCT06450886: Long-term Extension Study of Ulviprubart (ABC008) in Subjects with Inclusion Body Myositis

Active, not recruiting
2/3
270
US, RoW
Ulviprubart (ABC008)
Abcuro, Inc.
Inclusion Body Myositis (IBM)
01/29
04/29
NCT05721573: A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

Active, not recruiting
2/3
231
Europe, Canada, US, RoW
ABC008
Abcuro, Inc., Syneos Health
Inclusion Body Myositis
11/25
12/25
NCT06408727: Intermediate Expanded Access Protocol CNMAu8.EAP04

Available
N/A
US
CNM-Au8
Clene Nanomedicine, National Institute of Neurological Disorders and Stroke (NINDS)
ALS, Amyotrophic Lateral Sclerosis, PALS
 
 
NCT05597436: Intermediate-Sized Expanded Access Study

No Longer Available
N/A
US
Trehalose, SLS-005 Intravenous Trehalose Injection 90.5 mg/mL
Seelos Therapeutics, Inc., Massachusetts General Hospital, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH)
Amyotrophic Lateral Sclerosis
 
 
CNMAu8.EAP02, NCT05281484: Two Intermediate Expanded Access Protocols (EAP) CNMAu8.EAP01 and for ALS

Available
N/A
US
CNM-Au8, Nanocrystalline gold
Clene Nanomedicine
Amyotrophic Lateral Sclerosis
 
 
Arcila-Londono, Ximena
COURAGE-ALS, NCT04944784 / 2020-004040-29: A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)

Terminated
3
489
Europe, Canada, US, RoW
Reldesemtiv, Placebo
Cytokinetics
Amyotrophic Lateral Sclerosis
07/23
07/23
COURAGE OLE, NCT05442775 / 2021-004727-33: A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)

Terminated
3
71
Europe, Canada, US, RoW
Reldesemtiv
Cytokinetics, Cytokinetics Inc
Amyotrophic Lateral Sclerosis
06/23
06/23
XT-150-1-0402, NCT06704347: Safety Study of XT-150 in Participants with ALS

Not yet recruiting
1
8
US
XT-150
Xalud Therapeutics, Inc.
Amyotrophic Lateral Sclerosis (ALS)
06/26
06/26
CNMAu8.EAP02, NCT05281484: Two Intermediate Expanded Access Protocols (EAP) CNMAu8.EAP01 and for ALS

Available
N/A
US
CNM-Au8, Nanocrystalline gold
Clene Nanomedicine
Amyotrophic Lateral Sclerosis
 
 
Wagoner, Mary
COMBAT-ALS, NCT04057898 / 2019-003549-14: Evaluation of MN-166 (ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients with ALS

Recruiting
2/3
230
Canada, US
MN-166, ibudilast, placebo
MediciNova
Amyotrophic Lateral Sclerosis
12/25
12/26
Duthie, Beverley
CNMAu8.EAP02, NCT05281484: Two Intermediate Expanded Access Protocols (EAP) CNMAu8.EAP01 and for ALS

Available
N/A
US
CNM-Au8, Nanocrystalline gold
Clene Nanomedicine
Amyotrophic Lateral Sclerosis
 
 
Ward, Michelle
NCT06408727: Intermediate Expanded Access Protocol CNMAu8.EAP04

Available
N/A
US
CNM-Au8
Clene Nanomedicine, National Institute of Neurological Disorders and Stroke (NINDS)
ALS, Amyotrophic Lateral Sclerosis, PALS
 
 
CNMAu8.EAP02, NCT05281484: Two Intermediate Expanded Access Protocols (EAP) CNMAu8.EAP01 and for ALS

Available
N/A
US
CNM-Au8, Nanocrystalline gold
Clene Nanomedicine
Amyotrophic Lateral Sclerosis
 
 
Carlson, Danielle
NCT06450886: Long-term Extension Study of Ulviprubart (ABC008) in Subjects with Inclusion Body Myositis

Active, not recruiting
2/3
270
US, RoW
Ulviprubart (ABC008)
Abcuro, Inc.
Inclusion Body Myositis (IBM)
01/29
04/29
NCT05721573: A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

Active, not recruiting
2/3
231
Europe, Canada, US, RoW
ABC008
Abcuro, Inc., Syneos Health
Inclusion Body Myositis
11/25
12/25
Nasri, Mohamad
NCT06408727: Intermediate Expanded Access Protocol CNMAu8.EAP04

Available
N/A
US
CNM-Au8
Clene Nanomedicine, National Institute of Neurological Disorders and Stroke (NINDS)
ALS, Amyotrophic Lateral Sclerosis, PALS
 
 
Nagaraj, Arun
REMODEL-1, NCT05147220 / 2020-005899-36: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting
3
800
Europe, US, RoW
Remibrutinib, LOU064, Teriflunomide
Novartis Pharmaceuticals, Novartis Pharma AG
Relapsing Multiple Sclerosis
04/26
10/30
NCT05671055: CogMS - A Real-world Study Into Cognitive Impairment in People With Multiple Sclerosis

Completed
N/A
300
Europe, US
Custom study version of icompanion app
icometrix, Bristol-Myers Squibb
Multiple Sclerosis
12/23
12/23
Heitzman
NCT05721573: A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

Active, not recruiting
2/3
231
Europe, Canada, US, RoW
ABC008
Abcuro, Inc., Syneos Health
Inclusion Body Myositis
11/25
12/25
Halawani, Hanan Al
NCT06450886: Long-term Extension Study of Ulviprubart (ABC008) in Subjects with Inclusion Body Myositis

Active, not recruiting
2/3
270
US, RoW
Ulviprubart (ABC008)
Abcuro, Inc.
Inclusion Body Myositis (IBM)
01/29
04/29
NCT05721573: A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

Active, not recruiting
2/3
231
Europe, Canada, US, RoW
ABC008
Abcuro, Inc., Syneos Health
Inclusion Body Myositis
11/25
12/25
Coriddi, Angela
CNMAu8.EAP02, NCT05281484: Two Intermediate Expanded Access Protocols (EAP) CNMAu8.EAP01 and for ALS

Available
N/A
US
CNM-Au8, Nanocrystalline gold
Clene Nanomedicine
Amyotrophic Lateral Sclerosis
 
 
Aburashed, Rany
REMODEL-1, NCT05147220 / 2020-005899-36: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting
3
800
Europe, US, RoW
Remibrutinib, LOU064, Teriflunomide
Novartis Pharmaceuticals, Novartis Pharma AG
Relapsing Multiple Sclerosis
04/26
10/30
NCT05686044: A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD

Completed
2/3
320
US
Buntanetap/Posiphen, Posiphen Tartrate, Placebo
Annovis Bio Inc.
Alzheimer Disease
02/24
02/24
Hua, Vivian
NCT06450886: Long-term Extension Study of Ulviprubart (ABC008) in Subjects with Inclusion Body Myositis

Active, not recruiting
2/3
270
US, RoW
Ulviprubart (ABC008)
Abcuro, Inc.
Inclusion Body Myositis (IBM)
01/29
04/29
NCT05721573: A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

Active, not recruiting
2/3
231
Europe, Canada, US, RoW
ABC008
Abcuro, Inc., Syneos Health
Inclusion Body Myositis
11/25
12/25
Naddaf, Elie
NCT05721573: A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

Active, not recruiting
2/3
231
Europe, Canada, US, RoW
ABC008
Abcuro, Inc., Syneos Health
Inclusion Body Myositis
11/25
12/25
RESET-MG, NCT06359041: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis

Recruiting
1/2
12
US
CABA-201
Cabaletta Bio
Generalized Myasthenia Gravis (gMG)
09/29
09/29
Arroyo, Victor Bolivar
REMODEL-1, NCT05147220 / 2020-005899-36: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting
3
800
Europe, US, RoW
Remibrutinib, LOU064, Teriflunomide
Novartis Pharmaceuticals, Novartis Pharma AG
Relapsing Multiple Sclerosis
04/26
10/30
Ngwueke, Agatha
REMODEL-1, NCT05147220 / 2020-005899-36: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting
3
800
Europe, US, RoW
Remibrutinib, LOU064, Teriflunomide
Novartis Pharmaceuticals, Novartis Pharma AG
Relapsing Multiple Sclerosis
04/26
10/30
ART-AIN IIB-2, NCT06206564: Artesunate Ointment for the Treatment of Anal HSIL in HIV-negative Participants

Recruiting
2
48
US
Artesunate ointment, Artesunic acid, Dihydroartemisinin (DHA), Artemisinin, Placebo, placebo ointment
Frantz Viral Therapeutics, LLC, Laser Surgery Care, LLC, Anal Dysplasia Clinic MidWest
Anal High-grade Squamous Intraepithelial Lesion, Anal HSIL, Anal HPV Infection
12/25
12/25
Rucker, Haley
MAGIC, NCT06282159: A Phase 2 Study to Evaluate DNTH103 in Adults with Generalized Myasthenia Gravis

Recruiting
2
60
Europe, Canada, US, RoW
DNTH103, Placebo
Dianthus Therapeutics
Myasthenia Gravis, Generalized
12/25
12/27
Rice, Danielle
REMODEL-1, NCT05147220 / 2020-005899-36: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting
3
800
Europe, US, RoW
Remibrutinib, LOU064, Teriflunomide
Novartis Pharmaceuticals, Novartis Pharma AG
Relapsing Multiple Sclerosis
04/26
10/30
Poulos, Cati
NCT06069934: Pridopidine in Amyotrophic Lateral Sclerosis (EAP 2)

No Longer Available
N/A
US
Pridopidine
Prilenia, Massachusetts General Hospital, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH)
Amyotrophic Lateral Sclerosis
 
 
Pinal, Amanda
NCT06069934: Pridopidine in Amyotrophic Lateral Sclerosis (EAP 2)

No Longer Available
N/A
US
Pridopidine
Prilenia, Massachusetts General Hospital, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH)
Amyotrophic Lateral Sclerosis
 
 

Download Options